Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The Hedgehog (Hh) signaling pathway is crucial for development and implicated in various solid cancers.
• Current therapies target Smoothened, a transmembrane protein in the Hh pathway.
• These therapies are ineffective when Hh pathway activation occurs downstream of Smoothened.

Purpose of the Study:

• To identify novel small-molecule antagonists targeting the final step of the Hh pathway: GLI-mediated transcription.
• To evaluate the efficacy of these inhibitors in preclinical cancer models with downstream Hh pathway activation.

Main Methods:

• A cellular screen was employed to identify inhibitors of GLI-mediated transcription.
• Genetic validation confirmed downstream pathway blockade by the identified compounds.
• In vitro proliferation assays and in vivo xenograft models were used to assess anti-cancer activity.

Main Results:

• Two novel small-molecule inhibitors of GLI-mediated gene transactivation were discovered.
• These compounds effectively blocked Hh pathway activity downstream of Smoothened.
• The inhibitors demonstrated potent inhibition of tumor cell proliferation in vitro and blocked tumor growth in vivo.

Conclusions:

• The identified compounds represent a new class of Hh pathway inhibitors targeting GLI transcription.
• These inhibitors are effective against cancers with downstream Hh pathway activation, offering a therapeutic strategy where upstream inhibitors fail.
• The findings support the development of GLI-targeted therapies for specific cancer types.